FIB-4 Calculator
Calculate the FIB-4 index from age, AST, ALT and platelets, and see whether advanced liver fibrosis looks unlikely, likely, or needs a second-line test.
FIB-4 Calculator
Liver fibrosis is scar tissue replacing working liver. It accumulates silently: a person can lose most of their functional liver mass before the first symptom appears, which is why staging fibrosis — not measuring enzymes — is what decides whether someone needs specialist care. For decades the reference standard was a liver biopsy, an invasive procedure with a small but real risk of bleeding and a sampling error that can misclassify a stage. The FIB-4 index exists because that trade-off became unacceptable at population scale.
The index came out of the APRICOT trial cohort, a study of patients co-infected with HIV and hepatitis C, where biopsies were logistically impossible for 832 participants. Sterling and colleagues tested routine laboratory values — age, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and platelet count — and found they predicted advanced fibrosis well enough to avoid most biopsies.[sterling-2006] Vallet-Pichard and colleagues then validated the same four variables in 847 biopsies from patients with hepatitis C alone, and the index stopped being an HIV study curiosity and became a general hepatology tool.[vallet-pichard-2007]
Two decades later the use case has shifted again. Fatty liver disease now affects roughly 37% of adults in the United States,[kanwal-2021-aga] and the question facing primary care is no longer "does this patient have liver disease" but "which of these many patients needs a specialist". The American Gastroenterological Association pathway puts FIB-4 first precisely because it is built from tests almost everyone has already had done.[kanwal-2021-aga] If you are here because a lab report printed a FIB-4 value and you want to know what it means, or because you are a clinician deciding whether to refer, this calculator answers the arithmetic question precisely and the clinical question only partly — the rest is in the sections below.
FIB-4 is a surrogate for fibrosis. It does not measure scar tissue; it measures three things that tend to move when scar tissue accumulates:
- Age. Fibrosis prevalence rises with age, so age sits in the numerator as a weighting factor.
- AST relative to ALT. As fibrosis progresses, the AST/ALT ratio tends to invert, so a higher AST raises the score.
- Platelet count. Portal hypertension and splenic sequestration lower platelets, so a falling count raises the score.
That is the whole model. There is no imaging, no proprietary marker and no cost beyond tests that are usually already on the panel — which is exactly why it is used as a triage step rather than a diagnostic test.
It is worth being explicit about what the number is not. A FIB-4 of 3.4 does not mean a person has cirrhosis, and a FIB-4 of 0.7 does not prove the liver is healthy. It shifts a probability: below a low cut-off, advanced fibrosis becomes unlikely enough that further testing can usually wait; above a high cut-off, it becomes likely enough that a second-line test is warranted. In between, the test has done its job by telling you it cannot decide.
You need four numbers, all from a standard liver panel and complete blood count:
- Age in years at the time of the blood draw. Use the age on the lab date, not the age at diagnosis.
- AST in U/L, exactly as reported.
- ALT in U/L, exactly as reported.
- Platelet count in ×10⁹/L. Most US labs report platelets as ×10³/µL, which is the same number — 200 ×10³/µL is 200 ×10⁹/L. If your lab reports 200,000/µL, drop the three zeros and enter 200.
Then choose a threshold set. The default uses the current consensus cut-offs of 1.3 and 2.67; the alternative shows the original validation cut-offs of 1.45 and 3.25 so you can compare against older publications that still use them.
Example 1 — a routine screening result. A 55-year-old with AST 40 U/L, ALT 50 U/L and platelets 200 ×10⁹/L. The index is (55 × 40) ÷ (200 × √50) = 2200 ÷ 1414.2 = 1.56. That sits between 1.3 and 2.67, so the calculator reports indeterminate. The correct next step is not another FIB-4; it is a second-line test such as vibration-controlled transient elastography (VCTE), which is what both the AGA pathway and the AASLD guidance recommend for this band.[rinella-2023-aasld]
Example 2 — a clearly low result. A 42-year-old with AST 22 U/L, ALT 30 U/L and platelets 260 ×10⁹/L. The index is (42 × 22) ÷ (260 × √30) = 924 ÷ 1424.0 = 0.65. Advanced fibrosis is unlikely, and in a primary-care pathway this result typically means no further liver-specific testing today, with re-checking driven by metabolic risk factors rather than by the score.
Example 3 — a clearly high result for a patient over 65. A 72-year-old with AST 48 U/L, ALT 40 U/L and platelets 150 ×10⁹/L. The index is (72 × 48) ÷ (150 × √40) = 3456 ÷ 948.7 = 3.64. That is above both the 2.67 cut-off and the age-adjusted 2.0 cut-off, so the classification is unchanged by age — but the calculator still prints the age note, because the reason matters: at 65 and older, the specificity of the 2.67 cut-off drops to roughly 35%, meaning most positives in that age band are false positives.[mcpherson-2017]
Example 4 — the same numbers at two ages. AST 30 U/L, ALT 30 U/L, platelets 210 ×10⁹/L gives 0.87 at age 40 and 2.01 at age 92. The biology did not change; the weighting did. This is the single most common reason a FIB-4 result surprises people, and it is why the age-adjusted cut-off exists.
The square root applies to ALT alone, not to the entire denominator. Writing the denominator as √(platelets × ALT) is the most common transcription error, and it produces values off by roughly a factor of two — easily enough to move a patient across a cut-off.
The units cancel in the way that matters: AST and ALT must both be in U/L, and the platelet count must be in 10⁹/L, which is numerically identical to 10³/µL. Age is in years. The result is dimensionless.
Manual step-through for the first example above:
- Multiply age by AST: 55 × 40 = 2200.
- Take the square root of ALT: √50 = 7.0711.
- Multiply by platelets: 200 × 7.0711 = 1414.2.
- Divide: 2200 ÷ 1414.2 = 1.5556.
- Round to two decimals the way labs do: 1.56.
A useful sanity check: with AST and ALT in the 30–50 U/L range and platelets near 200, a FIB-4 between 1.0 and 2.0 corresponds to roughly ages 40–70. Values far outside that band usually indicate either a very abnormal enzyme or a low platelet count rather than an arithmetic slip.
The original publications used 1.45 and 3.25. Sterling's validation set found that a value below 1.45 excluded advanced fibrosis with a negative predictive value of 90%, and a value above 3.25 confirmed it with a positive predictive value of 65%.[sterling-2006] In hepatitis C monoinfection, Vallet-Pichard reported a negative predictive value of 94.7% below 1.45 and a positive predictive value of 82.1% above 3.25.[vallet-pichard-2007]
Later, much larger fatty-liver cohorts settled on 1.3 and 2.67. The individual patient data meta-analysis by Mózes and colleagues is the clearest statement of where those numbers come from: across 37 studies, FIB-4 reached an AUROC of 0.76 for advanced fibrosis, and the cut-offs of below 1.3 and at or above 2.67 were the ones used in the sequential pathway with elastography.[mozes-2022]
| AUROC for advanced fibrosis | 0.765 | 0.85 | 0.76 |
| Negative predictive value at the low cut-off | 90% (below 1.45) | 94.7% (below 1.45) | — (below 1.3 used to rule out) |
| Specificity at the high cut-off | 97% (above 3.25) | 98.2% (above 3.25) | — (at or above 2.67 used to rule in) |
The practical consequence is that both sets describe the same test at different operating points. A value of 1.4 is indeterminate under the current set and low under the original one; a value of 2.9 is high under the current set and indeterminate under the original. For decision-making today, use the current set — the 1.3 and 2.67 thresholds are what the AGA pathway and AASLD guidance build their referral logic on.[kanwal-2021-aga]
| Below 1.3 | Advanced fibrosis unlikely | No liver-specific imaging today; manage metabolic risk and re-check on schedule |
| 1.3 to 2.67 | Cannot rule in or out | Second-line test, usually VCTE or an ELF-type blood test |
| At or above 2.67 | Advanced fibrosis likely | Referral to hepatology for staging and management |
| At or above 2.0 with age 65+ | Advanced fibrosis likely in this age band | Treat as elevated, with the caveat that false positives are common |
McPherson and colleagues examined 634 patients with biopsy-confirmed fatty liver disease grouped by age. FIB-4 performed acceptably in every group above 35, with AUROCs between 0.77 and 0.84 — but specificity at the high cut-off fell steadily with age, reaching about 35% at 65 and older. In other words, in older patients roughly two out of three "positive" FIB-4 results were wrong. The authors derived and validated an alternative upper cut-off of 2.0 for that age group, which restored specificity to 70% while keeping sensitivity at 77%.[mcpherson-2017]
At the other end, the test is weak where it is least needed: in patients 35 and younger the AUROC dropped to 0.60, close to a coin flip. A low FIB-4 in a young patient is reassuring mostly because advanced fibrosis is rare at that age, not because the test detects it well.
This is why the calculator prints the age-adjusted cut-off as a separate note instead of silently substituting it. The number 2.0 is a published proposal for a specific age band, not a universal replacement for 2.67, and a clinician needs to see which threshold produced the classification.
Roughly a third to a half of real-world FIB-4 values land between the cut-offs, and that is the test working as designed rather than failing. A triage test earns its place by making most results decisively low, some decisively high, and the ambiguous remainder someone else's problem to resolve with a better test.
The published pathway is explicit about the sequence. In the Mózes analysis, FIB-4 below 1.3 or at or above 2.67 was followed by elastography with cut-offs of 8.0 kPa and 10.0 kPa; the combination reached 66% sensitivity and 86% specificity for advanced fibrosis.[mozes-2022] The AASLD guidance describes the same shape: a non-invasive score first, then a second-line test for the indeterminate band, then referral for those who remain elevated.[rinella-2023-aasld]
What does not help is repeating the FIB-4 on the same sample, or averaging two FIB-4 values. The test has the resolution it has; the next step changes the test, not the repetition.
- It cannot stage fibrosis. It separates "advanced fibrosis is unlikely" from "advanced fibrosis is likely". It does not distinguish F1 from F2, and it cannot identify cirrhosis reliably on its own.
- It is not fibrosis-specific. Anything that raises AST or lowers platelets moves the index: heavy alcohol use, acute viral hepatitis, muscle injury, chemotherapy, immune thrombocytopenia, splenomegaly from another cause, or a recent infection.
- It is not validated for every population. The index was developed in HIV/HCV co-infection, validated in HCV monoinfection, and then re-validated in fatty liver disease. Performance in other chronic liver diseases is variable and should not be assumed.
- It does not replace a biopsy in ambiguous or discordant cases. When non-invasive results conflict with the clinical picture, histology still has a role.
- It does not measure liver function. A normal FIB-4 says nothing about synthetic function, portal pressure, or the presence of fat; those need bilirubin, albumin, INR and imaging.
- Use the age at the time of the blood draw. Age is a multiplier, so a year or two of drift changes the result more than people expect.
- Confirm the platelet unit before entering it. A platelet count entered as 200000 instead of 200 produces an index 1000 times too small, which reads as falsely reassuring.
- Do not compare a FIB-4 from today with one from five years ago without accounting for the age term. Part of any apparent progression is the arithmetic.
- Treat an AST-dominant pattern with suspicion. If AST is more than twice ALT, consider alcohol, muscle sources or advanced disease before trusting the score.
- Know your local pathway. Some systems use FIB-4 as the entry test, others use the NAFLD fibrosis score first; the cut-offs and referral routes differ.
- Do not order a FIB-4 to "screen" someone with no risk factors. The pre-test probability is so low that a positive result is more likely to be a false positive than a finding.
This calculator implements the published equation exactly, with one addition: when age is 65 or older and the current threshold set is selected, it also reports the age-adjusted upper cut-off of 2.0 proposed by McPherson and colleagues. That adjustment is a published proposal, not a universal standard, and some pathways continue to use 2.67 at all ages.
The tool does not validate inputs against reference ranges, does not flag implausible combinations (for example a platelet count of 400 with an AST of 300), and does not adjust for alcohol use, viral status, medication or comorbidity. It performs no unit conversion beyond the platelet equivalence between ×10⁹/L and ×10³/µL.
Results are not a diagnosis. Interpretation depends on the clinical context, the trend over time, and the test that follows. Anyone using this output to make a decision about their own care should discuss it with a clinician who can see the full picture — including the labs this calculator never asks for.[niddk-nafld]
- ❓ What is a normal FIB-4 index?
- ✅ There is no single normal value. A result below 1.3 is treated as low risk for advanced fibrosis, 1.3 to 2.67 as indeterminate, and 2.67 or above as high risk. Values below 1.0 are common in healthy younger adults.
- ❓ Can FIB-4 detect cirrhosis?
- ✅ It flags people in whom cirrhosis is likely enough to justify further testing, but it cannot confirm cirrhosis. Confirmation usually requires elastography, imaging, or clinical evidence of portal hypertension.
- ❓ Why does age appear in the formula?
- ✅ Fibrosis prevalence rises with age, so age acts as a weighting term that improves discrimination across populations. It also means the same labs produce a higher index in an older person.
- ❓ My platelets are reported as 200,000 per microliter. What do I enter?
- ✅ Enter 200. A count of 200 ×10³/µL equals 200 ×10⁹/L, which is the unit the formula expects. Entering 200000 gives a result a thousand times too low.
- ❓ Does an indeterminate result mean something is wrong?
- ✅ No. Between a third and a half of results land in that band by design. It means the score cannot separate low from high risk, so a second-line test such as elastography is the appropriate next step.
- ❓ Is FIB-4 useful in people under 35?
- ✅ Weakly. Published data show an AUROC near 0.60 in that age group, close to chance. A low value is reassuring mainly because advanced fibrosis is rare at that age.
- ❓ Why do some sources use 1.45 and 3.25 instead of 1.3 and 2.67?
- ✅ The first two come from the original 2006 and 2007 validation studies. Larger fatty-liver cohorts later converged on 1.3 and 2.67, which is what current guidance uses.
- ❓ Can I use FIB-4 if I have hepatitis B?
- ✅ It is used, but it was developed and validated in hepatitis C and fatty liver disease. Performance in hepatitis B varies between studies, so local guidance should decide how much weight to give it.
- ❓ Does alcohol affect the result?
- ✅ Yes. Alcohol raises AST more than ALT and can lower platelets, so heavy drinking inflates the index independently of fibrosis. That can produce a high result without advanced fibrosis.
- ❓ How often should FIB-4 be repeated?
- ✅ There is no universal interval. Repeating every one to three years is common in metabolic liver disease, with frequency driven by risk factors such as diabetes and obesity rather than by the score itself.
- ❓ What happens after a high FIB-4?
- ✅ Typically referral to hepatology for staging, which may involve elastography, additional blood markers, or in selected cases a biopsy. The score alone does not establish a diagnosis.
- ❓ Is this calculator a substitute for medical advice?
- ✅ No. It performs a published arithmetic calculation and reports the published interpretation bands. Diagnosis and management require a clinician who can review the full record.
References
- [1]Sterling, R.K., Lissen, E., Clumeck, N., et al. (2006). "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection." *Hepatology*, 43(6), 1317–1325.
- [2]Vallet-Pichard, A., Mallet, V., Nalpas, B., et al. (2007). "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest." *Hepatology*, 46(1), 32–36.
- [3]McPherson, S., Hardy, T., Dufour, J.F., et al. (2017). "Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis." *American Journal of Gastroenterology*, 112(5), 740–751.
- [4]Mózes, F.E., Lee, J.A., Selvaraj, E.A., et al. (2022). "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis." *Gut*, 71(5), 1006–1019.
- [5]Kanwal, F., Shubrook, J.H., Adams, L.A., et al. (2021). "Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease." *Gastroenterology*, 161(5), 1657–1669.
- [6]Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., et al. (2023). "AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease." *Hepatology*, 77(5), 1797–1835.
- [7]National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2024). "NAFLD & NASH."
Last updated: November 16, 2026
UnByte — Independent Software Engineering
Every calculator references authoritative sources — Editorial policy

